RxDoctor Payments Data

Irfan Lalani, MD

Neurology · Sugar Land, TXNPI 1154472017

Payments from drug & device makers

$2,952in general payments, 2019–2025

Across 56 payments — averaging $52.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Nevro Corp.$378
  • Teva Pharmaceuticals USA, Inc.$145
  • Medtronic$142
  • Eisai Inc.$110
  • UCB, Inc.$108
  • plus $223 from 6 others
$1,865in research payments, 2019–2025

Across 1 payment — averaging $1865.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

What the payments were for

  • Travel & lodging$1,49251%
  • Food & beverage$1,34946%
  • Education$1114%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,952 in reported general payments places this provider in the 50th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$504,338
Medicare patients
1,080
Services billed
3,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate23$171,055
VumerityDiroximel Fumarate13$104,983
RytaryCarbidopa/Levodopa47$60,297
UbrelvyUbrogepant22$38,190
GlatopaGlatiramer Acetate11$27,852
BotoxOnabotulinumtoxina17$20,526
Carbidopa-LevodopaCarbidopa/Levodopa301$8,848
Memantine Hcl183$7,563
Pregabalin140$6,338
Duloxetine Hcl146$6,291
Oxcarbazepine77$4,995
Gabapentin148$3,993
Donepezil Hcl287$3,938
Mycophenolate Mofetil15$3,938
Divalproex Sodium ErDivalproex Sodium34$3,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$49$171,05523 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide$26$66,51880 claims
AbbVieUbrelvy, Botox$72$58,71639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,246 neurology providers in Texas.

Other neurology in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →